New Data Analysis from B305 Clinical Trial Presented at ERS
Release Date: 08/09/2014 12:00am
Pharmaceutical development company Pharmaxis today announced that a positive new data analysis from its large scale study of Bronchitol in patients with bronchiectasis (B305) is being presented at the European Respiratory Society (ERS) meeting taking place in Germany from 6-10 September 2014.
The late breaking abstract, to be presented in a thematic poster session by Dr Anthony de Soyza, Honorary Consultant Physician and Senior Lecturer in Respiratory Medicine at Newcastle University UK, examined a higher risk subgroup from the trial who, despite best standard of care, continued to suffer breathlessness even at rest and frequent exacerbation.
In this subgroup analysis of patients from the clinical trial who were at higher risk of further exacerbations, Bronchitol demonstrated both clinically important and significant improvements in exacerbation rate, antibiotic use and total SGRQ* scores on top of existing best standard of care over a 12 month period. The authors concluded the post-hoc findings suggest a greater effect from Bronchitol in higher risk patients than observed in the broader non-CF bronchiectasis population studied.
Categories: News and Media